49 research outputs found
Intersubjective systems theory: A fallibalist journey.
Intersubjective systems theory is the view that personal experience always emerges, maintains itself, and transforms in relational contexts. It is held for reasons of personal inclinations, philosophical belief, and clinical conviction. As a clinical sensibility, it primarily includes an emphasis on the emotional convictions or organizing principles that systematize experience, the personal engagement of the analyst, and the refusal to argue about reality. Key words: intersubjective; system; psychoanalysis; fallibilism; reductionism; phenomenology; experience; contextualism; hermeneutics We grace our beliefs by calling them theories. (Emmanuel Ghent) Why is intersubjective systems theory so compelling for me? First, a few words are provided about this psychoanalytic approach. This theory examines the field-two personal worlds of experience in the system they create and from which they emerge-in human development and in any form of psychoanalytic treatment. Because of this focus, intersubjectivity theory also implies a contextualist view of development and of pathogenesis, describes the emergence and modification of subjectivity (the experiential world), and defines all these processes as irreducibly relational. The observational/participatory focus is the evolving psychological field constituted by the interplay between the differently organized experiential worlds of child and caregivers, patient and analyst, and so on. Informally, it means I am always trying not only to describe experience (yours, mine, and ours) in this temporal-relational context but also to understand in what relational contexts we became the people who participate and experience as we do
Lessons learned from additional research analyses of unsolved clinical exome cases
BACKGROUND:
Given the rarity of most single-gene Mendelian disorders, concerted efforts of data exchange between clinical and scientific communities are critical to optimize molecular diagnosis and novel disease gene discovery.
METHODS:
We designed and implemented protocols for the study of cases for which a plausible molecular diagnosis was not achieved in a clinical genomics diagnostic laboratory (i.e. unsolved clinical exomes). Such cases were recruited to a research laboratory for further analyses, in order to potentially: (1) accelerate novel disease gene discovery; (2) increase the molecular diagnostic yield of whole exome sequencing (WES); and (3) gain insight into the genetic mechanisms of disease. Pilot project data included 74 families, consisting mostly of parent-offspring trios. Analyses performed on a research basis employed both WES from additional family members and complementary bioinformatics approaches and protocols.
RESULTS:
Analysis of all possible modes of Mendelian inheritance, focusing on both single nucleotide variants (SNV) and copy number variant (CNV) alleles, yielded a likely contributory variant in 36% (27/74) of cases. If one includes candidate genes with variants identified within a single family, a potential contributory variant was identified in a total of ~51% (38/74) of cases enrolled in this pilot study. The molecular diagnosis was achieved in 30/63 trios (47.6%). Besides this, the analysis workflow yielded evidence for pathogenic variants in disease-associated genes in 4/6 singleton cases (66.6%), 1/1 multiplex family involving three affected siblings, and 3/4 (75%) quartet families. Both the analytical pipeline and the collaborative efforts between the diagnostic and research laboratories provided insights that allowed recent disease gene discoveries (PURA, TANGO2, EMC1, GNB5, ATAD3A, and MIPEP) and increased the number of novel genes, defined in this study as genes identified in more than one family (DHX30 and EBF3).
CONCLUSION:
An efficient genomics pipeline in which clinical sequencing in a diagnostic laboratory is followed by the detailed reanalysis of unsolved cases in a research environment, supplemented with WES data from additional family members, and subject to adjuvant bioinformatics analyses including relaxed variant filtering parameters in informatics pipelines, can enhance the molecular diagnostic yield and provide mechanistic insights into Mendelian disorders. Implementing these approaches requires collaborative clinical molecular diagnostic and research efforts
Neuropsychiatric Symptom Burden across Neurodegenerative Disorders and its Association with Function
White matter hyperintensity burden predicts cognitive but not motor decline in Parkinson's disease. Results from the ONDRI
Genetic errors of immunity distinguish pediatric non-malignant lymphoproliferative disorders
Background
Pediatric non-malignant lymphoproliferative disorders (PLPD) are clinically and genetically heterogeneous. Long-standing immune dysregulation and lymphoproliferation in children may be life-threatening, and a paucity of data exists to guide evaluation and treatment of children with PLPD.
Objective
The primary objective of this study was to ascertain the spectrum of genomic immunologic defects in PLPD. Secondary objectives included characterization of clinical outcomes and associations between genetic diagnoses and those outcomes.
Methods
PLPD was defined by persistent lymphadenopathy, lymph organ involvement, or lymphocytic infiltration for more than 3 months, with or without chronic or significant EBV infection. Fifty-one subjects from 47 different families with PLPD were analyzed using whole exome sequencing (WES).
Results
WES identified likely genetic errors of immunity in 51% to 62% of families (53% to 65% of affected children). Presence of a genetic etiology was associated with younger age and hemophagocytic lymphohistiocytosis. Ten-year survival for the cohort was 72.4%, and patients with viable genetic diagnoses had a higher survival rate (82%) compared to children without a genetic explanation (48%, p = 0.03). Survival outcomes for individuals with EBV-associated disease and no genetic explanation were particularly worse than outcomes for subjects with EBV-associated disease and a genetic explanation (17% vs. 90%; p = 0.002). Ascertainment of a molecular diagnosis provided targetable treatment options for up to 18 individuals and led to active management changes for 12 patients.
Conclusion
PLPD therefore defines children with high risk for mortality, and WES informs clinical risks and therapeutic opportunities for this diagnosis